FDAapproval65% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for venlafaxine.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Urology · Bladder Pain Syndrome
- Sub-indication
- General
Related signal: Venlafaxine Shows Promise in Treating Bladder Pain Syndrome with Behavioral Intervention